Computer-aided analysis of structural properties and epitopes of Iranian HPV-16 E7 oncoprotein

Abstract

Infection by human papillomavirus type 16 (HPV-16) is the cause of 50% or more of cervical cancers in women. The E7 oncoprotein of HPV-16 has long been known as a potent immortalizing and transforming agent. We used different servers like PseAAC, MHC_binding, MHC_II_binding and Expasy for the present computational prediction. The results for T cell epitopes showed that B1501, A0203, A0201, A0202, A6801 and DRB0405 alleles had lower IC50 than other alleles. We also predicted several peptides with the best binding affinities for alleles of the most frequent MHC class I and II alleles of the various ethnic groups living in the different region of Iran. Two peptides (26-35) and (44-52) were predicted as B-cell epitopes. According to this analysis 1 N-glycosylation site, 2 PKC sites, 4 CK2 sites and 3 disulfide sites were predicted. Our computational study predicted that B cell epitope 1 was Casein kinase II phosphorylated (site No. 31) and glycosylated (site No. 29). Putative MHC-I epitopes 3 and 5 and MHC-II epitopes 19, 21 and 26 were predicted to be casein kinase II phosphorylated. MHC-II epitopes 19 and 21 was predicted to be glycosylated. T cell epitopes 1, 13, 16 and 24 were demonstrated to be kinase C phosphorylated. The result of this analysis for Iranian HPV-16 E7 also indicated that 21.43%, 18.37% and 60.20% of the protein were in the α-helix, extended strand and random coil respectively.

Designing of CD8⁺ and CD8⁺-overlapped CD4⁺ epitope vaccine by targeting late and early proteins of human papillomavirus

“…79 Immunoinformatics approaches have played a vital role in the qualitative screening of multiple genomes to predict target epitopes, which provides a rational design to enhance the T-cell immune responses in a cost-effective manner. 42,80,81 The possibility of antigen identification at the molecular level has enabled sensible designing of peptide vaccines. An advantage of the epitope-based vaccines is that they have the potential to induce high dosage of immunogenicity at a lower cost.…”

Predicting Promiscuous T Cell Epitopes for Designing a Vaccine Against Streptococcus pyogenes

“…During 2006 and in 2011, a universal vaccine with promising results for serogroup B meningococcus was identified [33,34]. Besides bacteria, this approach was tested against a variety of pathogenic organisms such as protozoan lishmania [35,36], HIV [38], influenza virus, Iranian HPV [39], and SARS-CoV [40]. In another study, B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer were predicted [41].…”